about
Cloning and sequence analysis of candidate human natural killer-enhancing factor genesProspective Clinical Testing of Regulatory Dendritic Cells in Organ TransplantationNovel technologies and emerging biomarkers for personalized cancer immunotherapyMelanoma-associated leukoderma - immunology in black and white?Cancer vaccinesValidation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerationsValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationAntioxidant function of recombinant human natural killer enhancing factor31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneRecommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialA randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyA systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Phase I dendritic cell p53 peptide vaccine for head and neck cancer.From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins.Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstemEctopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.Zinc in innate and adaptive tumor immunity.Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcelluloCancer immunotherapy using gene-modified dendritic cells.Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.Preamble to the 2015 SITC immunotherapy biomarkers taskforceDendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryPro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.Consensus nomenclature for CD8(+) T cell phenotypes in cancerRoute of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinomaDefining the critical hurdles in cancer immunotherapy.Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned.Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumabPitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients.Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease AfterSpontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasWeb-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting.
P50
Q24313519-5E5F3D96-7984-448D-BA41-D42A0CCDC6ABQ26767458-DFE0F4C3-C96F-4889-AED8-32F52AA5F162Q26770780-5FC59080-4AB3-41FC-B6C8-6DDCFA17CABFQ26850001-4F0DCE0A-6174-4695-9958-6C2E8BAD77D1Q27024438-3ECB6C22-3D24-403C-98A2-BB634A7164CFQ28066738-D76DD00C-82FD-430B-A933-51CAC67CE86EQ28075719-64D1FE6F-B546-4D9E-8100-0CDF1C0AEABCQ28299187-47726EF1-746E-46C1-9F56-343128C8816FQ28553703-6D6E771D-4D0B-4AA8-9C6C-0C56A0468B51Q28744503-E98008E7-76CA-439C-92ED-A888B57F706EQ30407940-5CB4A9AE-3AEE-4A41-B2AD-3A2F5588A65EQ30411499-B124E31C-EBA1-4D31-B62E-D3623DF5969DQ30438965-4E9E81E3-7C62-4BA3-BB72-4CDFAA14A877Q30440347-CFCEF3A1-59BC-42B7-846A-8C208E94C0DDQ30577847-00818821-5CA5-4F74-94FD-2DD585D4F323Q30636138-243E8903-449D-470D-AD3D-C5445F34BF43Q33614172-CB628316-5890-405E-B808-D1B3A0CAA11FQ33796170-0FF0CE56-FC4C-44E3-89F5-69B197C7227AQ34066925-C18D2EC0-02AA-4774-B135-F4E1E48F3E1FQ34408184-E8B3FFFA-8A8E-4ADE-8AA7-FEA408E76CAFQ34461524-D6E8D7DA-032F-41C5-8C15-C5C21F4BFEE5Q34666875-0859E878-6A6E-4918-8BA8-4EF2AA694302Q34729334-BA8FA128-F013-4249-B234-9C562BCCDB67Q34979511-5EACD58B-A606-4574-B579-1F1F9FE259DEQ35212166-3E61DA8C-4636-4520-AF35-31C587C2F9C2Q35239272-892E0920-812E-4D95-BEEC-6AE4081BE718Q35298744-C30F5EF9-E914-43EE-A51B-4E0758321324Q35698637-FE6B2B64-91C9-408F-96A5-B390D9F1E9D4Q35798822-542496B2-553C-47CB-AE40-7C7D34A0EAA5Q35871590-966E3F31-5383-471E-A856-94B03CE8F0F3Q35916968-0A8C682F-26C0-49CE-BE8D-107F27AD1049Q36061606-06F41098-2065-41D6-A25A-9CF07D9F6DA8Q36114626-BB72B1BD-6CC5-4453-A5DC-CFC02B67E055Q36278320-04DE2C6D-4991-433E-B5E7-4766E4405111Q36286948-817F27A5-313A-403E-B84B-638ADCC08B57Q36320424-E8BF94D2-713A-434D-8C14-242532DD8ED3Q36346631-F35A536A-3177-489E-A933-0B2CFE195F12Q36462618-EFA0A5C1-7531-4368-B365-67A977BA9228Q36478070-A1A241E3-E7A3-4D80-A4D5-D64741A178C9Q36788528-4321D4D8-4B0D-405E-9695-D2C4ABE64F24
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Lisa H. Butterfield
@ast
Lisa H. Butterfield
@en
Lisa H. Butterfield
@es
Lisa H. Butterfield
@nl
Lisa H. Butterfield
@sl
type
label
Lisa H. Butterfield
@ast
Lisa H. Butterfield
@en
Lisa H. Butterfield
@es
Lisa H. Butterfield
@nl
Lisa H. Butterfield
@sl
prefLabel
Lisa H. Butterfield
@ast
Lisa H. Butterfield
@en
Lisa H. Butterfield
@es
Lisa H. Butterfield
@nl
Lisa H. Butterfield
@sl
P244
P106
P1153
7004319517
P21
P214
7980149198346974940002
P244
n2017182802
P31
P496
0000-0002-3439-9844
P5008
P735
P7859
lccn-n2017182802